The tests that were being used to identify HER-2 status in advanced breast cancer patients who could potentially respond to Herceptin Â® treatment were both unreliable and inaccurate. Since studies have shown Herceptin® combined with chemotherapy increases both response and survival rates in these HER-2+ breast cancer patients, it was obviously important to find a way to improve these tests.32
Researchers used the avidin/biotin system to help overcome the difficulty. Biotinylated HerceptinÂ® was able to accurately detect patients with HER-2 amplified tumors. It was also discovered to be a predictor of clinical outcome, since those that it did detect were likely to benefit from HerceptinÂ® treatment. This was because the researchers were able to evaluate the availability of trastuzumab-binding sites on individual tumors.32
Disclaimer: This website is not intended to replace professional consultation, diagnosis, or treatment by a licensed physician. If you require any medical related advice, contact your physician promptly. Information at Biotin.com is exclusively of a general reference nature. Do not disregard medical advice or delay treatment as a result of accessing information at this site.
A protein in egg whites.9
Attached to a biotin molecule.9